Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Pure antiestrogens yield higher response rates than SERMs
February 10th, 2005
According to a study from England, "Following tamoxifen, the first selective estrogen receptor modulator (SERM), a number of other antiestrogens have been developed." "The first-generation SERMs exhibit cross-resistance with tamoxifen and have agonist effects on the uterus. Toremifene has equal efficacy to tamoxifen and may be useful as a tamoxifen alternative. Efficacy results for droloxifene and idoxifene were disappointing and their clinical development ceased," said J.F.R. Robertson and colleagues, City Hospital, Nottingham. They continued, "Response rates for second-generation SERMs such as raloxifene and arzoxifene are also not high, although...
Source: Women's Health Weekly (2005-02-10)
|
